A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Clinical trial NCT05496231 · COMPLETED

Trial details

NCT number: NCT05496231
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cervical Intraepithelial Neoplasia

Start date: 2022-08-22
Primary completion: 2024-02-23
Enrollment: 1080

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.